nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—ADRA1A—polycystic ovary syndrome	0.747	1	CbGaD
Zuclopenthixol—Body temperature decreased—Metformin—polycystic ovary syndrome	0.00333	0.0656	CcSEcCtD
Zuclopenthixol—Hypothermia—Metformin—polycystic ovary syndrome	0.00333	0.0656	CcSEcCtD
Zuclopenthixol—Rhinorrhoea—Metformin—polycystic ovary syndrome	0.0023	0.0454	CcSEcCtD
Zuclopenthixol—Nasal congestion—Metformin—polycystic ovary syndrome	0.00149	0.0293	CcSEcCtD
Zuclopenthixol—Migraine—Metformin—polycystic ovary syndrome	0.00133	0.0263	CcSEcCtD
Zuclopenthixol—Liver function test abnormal—Metformin—polycystic ovary syndrome	0.00125	0.0246	CcSEcCtD
Zuclopenthixol—Breast disorder—Metformin—polycystic ovary syndrome	0.00122	0.0241	CcSEcCtD
Zuclopenthixol—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00121	0.0239	CcSEcCtD
Zuclopenthixol—Sweating increased—Metformin—polycystic ovary syndrome	0.00114	0.0225	CcSEcCtD
Zuclopenthixol—Neutropenia—Metformin—polycystic ovary syndrome	0.00109	0.0216	CcSEcCtD
Zuclopenthixol—Drowsiness—Metformin—polycystic ovary syndrome	0.00104	0.0206	CcSEcCtD
Zuclopenthixol—HTR2A—urine—polycystic ovary syndrome	0.00102	0.109	CbGeAlD
Zuclopenthixol—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000986	0.0195	CcSEcCtD
Zuclopenthixol—CYP2D6—urine—polycystic ovary syndrome	0.000927	0.0993	CbGeAlD
Zuclopenthixol—Oedema peripheral—Metformin—polycystic ovary syndrome	0.000922	0.0182	CcSEcCtD
Zuclopenthixol—Connective tissue disorder—Metformin—polycystic ovary syndrome	0.00092	0.0181	CcSEcCtD
Zuclopenthixol—Propericiazine—ADRA1B—polycystic ovary syndrome	0.000895	0.109	CrCbGaD
Zuclopenthixol—Eye disorder—Metformin—polycystic ovary syndrome	0.000875	0.0173	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Metformin—polycystic ovary syndrome	0.000869	0.0171	CcSEcCtD
Zuclopenthixol—Angiopathy—Metformin—polycystic ovary syndrome	0.00085	0.0168	CcSEcCtD
Zuclopenthixol—Immune system disorder—Metformin—polycystic ovary syndrome	0.000846	0.0167	CcSEcCtD
Zuclopenthixol—Erythema—Metformin—polycystic ovary syndrome	0.000815	0.0161	CcSEcCtD
Zuclopenthixol—Malnutrition—Metformin—polycystic ovary syndrome	0.000815	0.0161	CcSEcCtD
Zuclopenthixol—Flatulence—Metformin—polycystic ovary syndrome	0.000803	0.0158	CcSEcCtD
Zuclopenthixol—Flupentixol—ADRA1A—polycystic ovary syndrome	0.000768	0.094	CrCbGaD
Zuclopenthixol—Vision blurred—Metformin—polycystic ovary syndrome	0.000768	0.0152	CcSEcCtD
Zuclopenthixol—Tremor—Metformin—polycystic ovary syndrome	0.000764	0.0151	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Metformin—polycystic ovary syndrome	0.000756	0.0149	CcSEcCtD
Zuclopenthixol—Malaise—Metformin—polycystic ovary syndrome	0.000735	0.0145	CcSEcCtD
Zuclopenthixol—Syncope—Metformin—polycystic ovary syndrome	0.000731	0.0144	CcSEcCtD
Zuclopenthixol—Palpitations—Metformin—polycystic ovary syndrome	0.00072	0.0142	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000716	0.0141	CcSEcCtD
Zuclopenthixol—Hypertension—Metformin—polycystic ovary syndrome	0.000704	0.0139	CcSEcCtD
Zuclopenthixol—Myalgia—Metformin—polycystic ovary syndrome	0.000694	0.0137	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000689	0.0136	CcSEcCtD
Zuclopenthixol—Discomfort—Metformin—polycystic ovary syndrome	0.000686	0.0135	CcSEcCtD
Zuclopenthixol—Shock—Metformin—polycystic ovary syndrome	0.000654	0.0129	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000652	0.0129	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000651	0.0128	CcSEcCtD
Zuclopenthixol—Skin disorder—Metformin—polycystic ovary syndrome	0.000646	0.0127	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Metformin—polycystic ovary syndrome	0.000643	0.0127	CcSEcCtD
Zuclopenthixol—Nefazodone—ADRA1B—polycystic ovary syndrome	0.000638	0.078	CrCbGaD
Zuclopenthixol—Anorexia—Metformin—polycystic ovary syndrome	0.000634	0.0125	CcSEcCtD
Zuclopenthixol—Hypotension—Metformin—polycystic ovary syndrome	0.000622	0.0123	CcSEcCtD
Zuclopenthixol—DRD5—female gonad—polycystic ovary syndrome	0.000609	0.0653	CbGeAlD
Zuclopenthixol—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000606	0.012	CcSEcCtD
Zuclopenthixol—Paraesthesia—Metformin—polycystic ovary syndrome	0.000597	0.0118	CcSEcCtD
Zuclopenthixol—Dyspnoea—Metformin—polycystic ovary syndrome	0.000593	0.0117	CcSEcCtD
Zuclopenthixol—Somnolence—Metformin—polycystic ovary syndrome	0.000591	0.0117	CcSEcCtD
Zuclopenthixol—Dyspepsia—Metformin—polycystic ovary syndrome	0.000586	0.0116	CcSEcCtD
Zuclopenthixol—Decreased appetite—Metformin—polycystic ovary syndrome	0.000578	0.0114	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000574	0.0113	CcSEcCtD
Zuclopenthixol—Fatigue—Metformin—polycystic ovary syndrome	0.000574	0.0113	CcSEcCtD
Zuclopenthixol—Constipation—Metformin—polycystic ovary syndrome	0.000569	0.0112	CcSEcCtD
Zuclopenthixol—DRD5—endocrine gland—polycystic ovary syndrome	0.000566	0.0607	CbGeAlD
Zuclopenthixol—Thioproperazine—ADRA1B—polycystic ovary syndrome	0.000562	0.0687	CrCbGaD
Zuclopenthixol—Feeling abnormal—Metformin—polycystic ovary syndrome	0.000548	0.0108	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000544	0.0107	CcSEcCtD
Zuclopenthixol—Abdominal pain—Metformin—polycystic ovary syndrome	0.000526	0.0104	CcSEcCtD
Zuclopenthixol—Asthenia—Metformin—polycystic ovary syndrome	0.000477	0.00941	CcSEcCtD
Zuclopenthixol—Pruritus—Metformin—polycystic ovary syndrome	0.000471	0.00928	CcSEcCtD
Zuclopenthixol—Diarrhoea—Metformin—polycystic ovary syndrome	0.000455	0.00898	CcSEcCtD
Zuclopenthixol—Dizziness—Metformin—polycystic ovary syndrome	0.00044	0.00868	CcSEcCtD
Zuclopenthixol—Quetiapine—ADRA1D—polycystic ovary syndrome	0.000434	0.0531	CrCbGaD
Zuclopenthixol—Nefazodone—ADRA1A—polycystic ovary syndrome	0.000429	0.0525	CrCbGaD
Zuclopenthixol—Vomiting—Metformin—polycystic ovary syndrome	0.000423	0.00834	CcSEcCtD
Zuclopenthixol—Rash—Metformin—polycystic ovary syndrome	0.000419	0.00827	CcSEcCtD
Zuclopenthixol—Dermatitis—Metformin—polycystic ovary syndrome	0.000419	0.00827	CcSEcCtD
Zuclopenthixol—Headache—Metformin—polycystic ovary syndrome	0.000417	0.00822	CcSEcCtD
Zuclopenthixol—Thioridazine—ADRA1B—polycystic ovary syndrome	0.000412	0.0504	CrCbGaD
Zuclopenthixol—Trazodone—ADRA1A—polycystic ovary syndrome	0.000397	0.0486	CrCbGaD
Zuclopenthixol—Nausea—Metformin—polycystic ovary syndrome	0.000395	0.00779	CcSEcCtD
Zuclopenthixol—Loxapine—ADRA1B—polycystic ovary syndrome	0.00038	0.0464	CrCbGaD
Zuclopenthixol—Thioproperazine—ADRA1A—polycystic ovary syndrome	0.000378	0.0463	CrCbGaD
Zuclopenthixol—Quetiapine—ADRA1B—polycystic ovary syndrome	0.00037	0.0453	CrCbGaD
Zuclopenthixol—ADRA1A—adipose tissue—polycystic ovary syndrome	0.000335	0.0359	CbGeAlD
Zuclopenthixol—DRD2—pituitary gland—polycystic ovary syndrome	0.00033	0.0354	CbGeAlD
Zuclopenthixol—HTR2A—embryo—polycystic ovary syndrome	0.000329	0.0352	CbGeAlD
Zuclopenthixol—Amoxapine—ADRA1A—polycystic ovary syndrome	0.000327	0.04	CrCbGaD
Zuclopenthixol—Clozapine—ADRA1B—polycystic ovary syndrome	0.000319	0.039	CrCbGaD
Zuclopenthixol—ADRA1A—adrenal gland—polycystic ovary syndrome	0.000301	0.0322	CbGeAlD
Zuclopenthixol—Chlorpromazine—ADRA1B—polycystic ovary syndrome	0.0003	0.0367	CrCbGaD
Zuclopenthixol—HRH1—endometrium—polycystic ovary syndrome	0.000288	0.0309	CbGeAlD
Zuclopenthixol—ADRA2A—endometrium—polycystic ovary syndrome	0.000283	0.0303	CbGeAlD
Zuclopenthixol—Thioridazine—ADRA1A—polycystic ovary syndrome	0.000277	0.0339	CrCbGaD
Zuclopenthixol—ADRA1A—endocrine gland—polycystic ovary syndrome	0.000261	0.028	CbGeAlD
Zuclopenthixol—ADRA2A—uterus—polycystic ovary syndrome	0.000261	0.0279	CbGeAlD
Zuclopenthixol—HRH1—adipose tissue—polycystic ovary syndrome	0.00026	0.0278	CbGeAlD
Zuclopenthixol—Trifluoperazine—ADRA1A—polycystic ovary syndrome	0.000257	0.0315	CrCbGaD
Zuclopenthixol—ADRA2A—pituitary gland—polycystic ovary syndrome	0.000256	0.0274	CbGeAlD
Zuclopenthixol—DRD2—endocrine gland—polycystic ovary syndrome	0.000256	0.0274	CbGeAlD
Zuclopenthixol—Loxapine—ADRA1A—polycystic ovary syndrome	0.000256	0.0313	CrCbGaD
Zuclopenthixol—ADRA2A—adipose tissue—polycystic ovary syndrome	0.000255	0.0273	CbGeAlD
Zuclopenthixol—Quetiapine—ADRA1A—polycystic ovary syndrome	0.000249	0.0305	CrCbGaD
Zuclopenthixol—HRH1—adrenal gland—polycystic ovary syndrome	0.000233	0.025	CbGeAlD
Zuclopenthixol—ADRA2A—adrenal gland—polycystic ovary syndrome	0.000229	0.0245	CbGeAlD
Zuclopenthixol—HTR2A—pituitary gland—polycystic ovary syndrome	0.000218	0.0233	CbGeAlD
Zuclopenthixol—HRH1—female gonad—polycystic ovary syndrome	0.000217	0.0233	CbGeAlD
Zuclopenthixol—HRH1—vagina—polycystic ovary syndrome	0.000216	0.0231	CbGeAlD
Zuclopenthixol—Clozapine—ADRA1A—polycystic ovary syndrome	0.000215	0.0262	CrCbGaD
Zuclopenthixol—ADRA2A—female gonad—polycystic ovary syndrome	0.000213	0.0229	CbGeAlD
Zuclopenthixol—ADRA2A—vagina—polycystic ovary syndrome	0.000212	0.0227	CbGeAlD
Zuclopenthixol—HRH1—endocrine gland—polycystic ovary syndrome	0.000202	0.0216	CbGeAlD
Zuclopenthixol—Chlorpromazine—ADRA1A—polycystic ovary syndrome	0.000202	0.0247	CrCbGaD
Zuclopenthixol—ADRA2A—endocrine gland—polycystic ovary syndrome	0.000198	0.0213	CbGeAlD
Zuclopenthixol—HTR2A—adrenal gland—polycystic ovary syndrome	0.000195	0.0208	CbGeAlD
Zuclopenthixol—HTR2A—vagina—polycystic ovary syndrome	0.00018	0.0193	CbGeAlD
Zuclopenthixol—HTR2A—endocrine gland—polycystic ovary syndrome	0.000169	0.0181	CbGeAlD
Zuclopenthixol—CYP2D6—female gonad—polycystic ovary syndrome	0.000165	0.0177	CbGeAlD
Zuclopenthixol—CYP2D6—endocrine gland—polycystic ovary syndrome	0.000154	0.0165	CbGeAlD
Zuclopenthixol—Clozapine—CYP1A1—polycystic ovary syndrome	0.000109	0.0134	CrCbGaD
Zuclopenthixol—HTR6—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.98e-05	0.000107	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—RBP4—polycystic ovary syndrome	1.97e-05	0.000107	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SCT—polycystic ovary syndrome	1.97e-05	0.000107	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NAMPT—polycystic ovary syndrome	1.97e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	1.97e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.96e-05	0.000106	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—ADRB2—polycystic ovary syndrome	1.95e-05	0.000105	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.94e-05	0.000105	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP11A1—polycystic ovary syndrome	1.94e-05	0.000105	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—SERPINE1—polycystic ovary syndrome	1.94e-05	0.000104	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.91e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—YAP1—polycystic ovary syndrome	1.91e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—DRD1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.9e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IRS2—polycystic ovary syndrome	1.9e-05	0.000103	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GAB1—polycystic ovary syndrome	1.89e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HMMR—polycystic ovary syndrome	1.89e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.88e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MTNR1B—polycystic ovary syndrome	1.88e-05	0.000102	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—YAP1—polycystic ovary syndrome	1.88e-05	0.000101	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—LEP—polycystic ovary syndrome	1.86e-05	0.000101	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.86e-05	0.0001	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GAB1—polycystic ovary syndrome	1.85e-05	0.0001	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FGF18—polycystic ovary syndrome	1.85e-05	9.99e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.84e-05	9.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKR1C3—polycystic ovary syndrome	1.83e-05	9.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—RBP4—polycystic ovary syndrome	1.83e-05	9.9e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—GNAS—polycystic ovary syndrome	1.83e-05	9.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.82e-05	9.81e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.81e-05	9.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP17A1—polycystic ovary syndrome	1.81e-05	9.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—GNAS—polycystic ovary syndrome	1.81e-05	9.75e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—INSR—polycystic ovary syndrome	1.8e-05	9.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.8e-05	9.71e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HSD3B1—polycystic ovary syndrome	1.8e-05	9.71e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PRL—polycystic ovary syndrome	1.79e-05	9.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—INSR—polycystic ovary syndrome	1.77e-05	9.58e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—INSR—polycystic ovary syndrome	1.77e-05	9.56e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.75e-05	9.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—INSR—polycystic ovary syndrome	1.74e-05	9.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.73e-05	9.34e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—NRG1—polycystic ovary syndrome	1.71e-05	9.26e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.71e-05	9.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—YAP1—polycystic ovary syndrome	1.71e-05	9.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.7e-05	9.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GAB1—polycystic ovary syndrome	1.69e-05	9.12e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.69e-05	9.11e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.69e-05	9.11e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.68e-05	9.09e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PGR—polycystic ovary syndrome	1.67e-05	9.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IRS1—polycystic ovary syndrome	1.66e-05	8.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.66e-05	8.96e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.66e-05	8.94e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.65e-05	8.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PGR—polycystic ovary syndrome	1.64e-05	8.87e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—LHB—polycystic ovary syndrome	1.64e-05	8.86e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PGR—polycystic ovary syndrome	1.64e-05	8.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.63e-05	8.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—INSR—polycystic ovary syndrome	1.61e-05	8.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PGR—polycystic ovary syndrome	1.61e-05	8.69e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—HSD3B2—polycystic ovary syndrome	1.6e-05	8.66e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—POMC—polycystic ovary syndrome	1.6e-05	8.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—INS—polycystic ovary syndrome	1.59e-05	8.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.58e-05	8.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—TH—polycystic ovary syndrome	1.56e-05	8.44e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKR1C1—polycystic ovary syndrome	1.55e-05	8.39e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GHRL—polycystic ovary syndrome	1.55e-05	8.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PLAT—polycystic ovary syndrome	1.55e-05	8.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IGF1—polycystic ovary syndrome	1.54e-05	8.31e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT2—polycystic ovary syndrome	1.54e-05	8.3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKR1C3—polycystic ovary syndrome	1.53e-05	8.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.53e-05	8.25e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.53e-05	8.25e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PLAT—polycystic ovary syndrome	1.52e-05	8.23e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GHRL—polycystic ovary syndrome	1.52e-05	8.23e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—SLC2A4—polycystic ovary syndrome	1.52e-05	8.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TNRC6B—polycystic ovary syndrome	1.51e-05	8.15e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.5e-05	8.12e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.5e-05	8.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.5e-05	8.08e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.5e-05	8.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PGR—polycystic ovary syndrome	1.49e-05	8.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ATF1—polycystic ovary syndrome	1.48e-05	8e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.48e-05	7.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.47e-05	7.95e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.47e-05	7.93e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IRS2—polycystic ovary syndrome	1.47e-05	7.93e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.46e-05	7.89e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.46e-05	7.87e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ATF1—polycystic ovary syndrome	1.45e-05	7.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.44e-05	7.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.44e-05	7.78e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.44e-05	7.76e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—LEP—polycystic ovary syndrome	1.44e-05	7.76e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP19A1—polycystic ovary syndrome	1.43e-05	7.72e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SULT2A1—polycystic ovary syndrome	1.43e-05	7.72e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.43e-05	7.71e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.42e-05	7.67e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.42e-05	7.66e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.41e-05	7.64e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.41e-05	7.62e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.39e-05	7.51e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PLAT—polycystic ovary syndrome	1.39e-05	7.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GHRL—polycystic ovary syndrome	1.39e-05	7.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.39e-05	7.48e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—RRM2—polycystic ovary syndrome	1.38e-05	7.47e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NGFR—polycystic ovary syndrome	1.37e-05	7.38e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—POMC—polycystic ovary syndrome	1.36e-05	7.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PRL—polycystic ovary syndrome	1.35e-05	7.31e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.34e-05	7.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NGFR—polycystic ovary syndrome	1.34e-05	7.25e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.34e-05	7.23e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.34e-05	7.22e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—YAP1—polycystic ovary syndrome	1.33e-05	7.2e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—POMC—polycystic ovary syndrome	1.33e-05	7.2e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PRL—polycystic ovary syndrome	1.33e-05	7.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Hemostasis—VEGFA—polycystic ovary syndrome	1.33e-05	7.19e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PRL—polycystic ovary syndrome	1.33e-05	7.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ATF1—polycystic ovary syndrome	1.33e-05	7.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.32e-05	7.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.31e-05	7.07e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.31e-05	7.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PRL—polycystic ovary syndrome	1.31e-05	7.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.29e-05	6.98e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.29e-05	6.95e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.29e-05	6.94e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.28e-05	6.94e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IRS1—polycystic ovary syndrome	1.28e-05	6.92e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NAMPT—polycystic ovary syndrome	1.28e-05	6.92e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.28e-05	6.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—GNAS—polycystic ovary syndrome	1.28e-05	6.89e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP11A1—polycystic ovary syndrome	1.27e-05	6.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.26e-05	6.83e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IRS2—polycystic ovary syndrome	1.26e-05	6.83e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.26e-05	6.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.26e-05	6.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.24e-05	6.69e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—LEP—polycystic ovary syndrome	1.24e-05	6.68e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—POMC—polycystic ovary syndrome	1.23e-05	6.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—INS—polycystic ovary syndrome	1.23e-05	6.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NGFR—polycystic ovary syndrome	1.22e-05	6.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—POMC—polycystic ovary syndrome	1.22e-05	6.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—NCOR1—polycystic ovary syndrome	1.22e-05	6.56e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PRL—polycystic ovary syndrome	1.21e-05	6.55e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKR1C3—polycystic ovary syndrome	1.2e-05	6.46e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—GNAS—polycystic ovary syndrome	1.19e-05	6.43e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IGF1—polycystic ovary syndrome	1.19e-05	6.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT2—polycystic ovary syndrome	1.19e-05	6.41e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP17A1—polycystic ovary syndrome	1.18e-05	6.35e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling by GPCR—IL6—polycystic ovary syndrome	1.18e-05	6.35e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.17e-05	6.33e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—GNAS—polycystic ovary syndrome	1.17e-05	6.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.17e-05	6.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—CYP1A1—polycystic ovary syndrome	1.15e-05	6.22e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.15e-05	6.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.15e-05	6.2e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.14e-05	6.13e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.13e-05	6.09e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.12e-05	6.03e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.11e-05	6.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRG1—polycystic ovary syndrome	1.11e-05	6.02e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IRS1—polycystic ovary syndrome	1.1e-05	5.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.1e-05	5.92e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRG1—polycystic ovary syndrome	1.09e-05	5.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.09e-05	5.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—MTHFR—polycystic ovary syndrome	1.07e-05	5.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRG1—polycystic ovary syndrome	1.07e-05	5.8e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—GNAS—polycystic ovary syndrome	1.07e-05	5.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—POMC—polycystic ovary syndrome	1.06e-05	5.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—INS—polycystic ovary syndrome	1.06e-05	5.71e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IGF1—polycystic ovary syndrome	1.02e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT2—polycystic ovary syndrome	1.02e-05	5.52e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—TH—polycystic ovary syndrome	1.02e-05	5.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.02e-05	5.49e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—VEGFA—polycystic ovary syndrome	1e-05	5.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRG1—polycystic ovary syndrome	9.97e-06	5.39e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—SLC2A4—polycystic ovary syndrome	9.91e-06	5.35e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	9.71e-06	5.24e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IRS2—polycystic ovary syndrome	9.54e-06	5.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IRS2—polycystic ovary syndrome	9.39e-06	5.07e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IRS2—polycystic ovary syndrome	9.37e-06	5.06e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—LEP—polycystic ovary syndrome	9.34e-06	5.04e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP19A1—polycystic ovary syndrome	9.31e-06	5.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IRS2—polycystic ovary syndrome	9.2e-06	4.97e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—LEP—polycystic ovary syndrome	9.19e-06	4.96e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—LEP—polycystic ovary syndrome	9.17e-06	4.95e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling by GPCR—IL6—polycystic ovary syndrome	9.08e-06	4.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—LEP—polycystic ovary syndrome	9e-06	4.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PPARG—polycystic ovary syndrome	8.71e-06	4.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—POMC—polycystic ovary syndrome	8.59e-06	4.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IRS2—polycystic ovary syndrome	8.54e-06	4.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—INS—polycystic ovary syndrome	8.54e-06	4.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—LEP—polycystic ovary syndrome	8.36e-06	4.51e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IRS1—polycystic ovary syndrome	8.33e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—GNAS—polycystic ovary syndrome	8.31e-06	4.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IRS1—polycystic ovary syndrome	8.2e-06	4.43e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IRS1—polycystic ovary syndrome	8.18e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IRS1—polycystic ovary syndrome	8.03e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—POMC—polycystic ovary syndrome	8.02e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—INS—polycystic ovary syndrome	7.98e-06	4.31e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—NCOR1—polycystic ovary syndrome	7.92e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—POMC—polycystic ovary syndrome	7.89e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—POMC—polycystic ovary syndrome	7.88e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—INS—polycystic ovary syndrome	7.85e-06	4.24e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—INS—polycystic ovary syndrome	7.83e-06	4.23e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—IL6—polycystic ovary syndrome	7.82e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—VEGFA—polycystic ovary syndrome	7.76e-06	4.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—POMC—polycystic ovary syndrome	7.73e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IGF1—polycystic ovary syndrome	7.72e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT2—polycystic ovary syndrome	7.71e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—INS—polycystic ovary syndrome	7.69e-06	4.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IGF1—polycystic ovary syndrome	7.59e-06	4.1e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT2—polycystic ovary syndrome	7.59e-06	4.1e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IGF1—polycystic ovary syndrome	7.58e-06	4.09e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT2—polycystic ovary syndrome	7.57e-06	4.09e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CYP1A1—polycystic ovary syndrome	7.51e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IRS1—polycystic ovary syndrome	7.46e-06	4.03e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IGF1—polycystic ovary syndrome	7.44e-06	4.02e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT2—polycystic ovary syndrome	7.43e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.33e-06	3.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.21e-06	3.89e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.2e-06	3.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—POMC—polycystic ovary syndrome	7.18e-06	3.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—INS—polycystic ovary syndrome	7.14e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	7.06e-06	3.81e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—polycystic ovary syndrome	7e-06	3.78e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—polycystic ovary syndrome	6.95e-06	3.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IGF1—polycystic ovary syndrome	6.91e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT2—polycystic ovary syndrome	6.9e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.68e-06	3.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SERPINE1—polycystic ovary syndrome	6.56e-06	3.54e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—polycystic ovary syndrome	5.9e-06	3.19e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—polycystic ovary syndrome	5.81e-06	3.14e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—polycystic ovary syndrome	5.79e-06	3.13e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—polycystic ovary syndrome	5.69e-06	3.07e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PPARG—polycystic ovary syndrome	5.68e-06	3.06e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—POMC—polycystic ovary syndrome	5.6e-06	3.02e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—INS—polycystic ovary syndrome	5.57e-06	3.01e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—polycystic ovary syndrome	5.36e-06	2.9e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—polycystic ovary syndrome	5.28e-06	2.85e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—polycystic ovary syndrome	5.04e-06	2.72e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.96e-06	2.68e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.95e-06	2.67e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.86e-06	2.62e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—polycystic ovary syndrome	4.62e-06	2.49e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—polycystic ovary syndrome	4.51e-06	2.44e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—polycystic ovary syndrome	3.49e-06	1.88e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—polycystic ovary syndrome	3.43e-06	1.85e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—polycystic ovary syndrome	3.42e-06	1.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—polycystic ovary syndrome	3.36e-06	1.81e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—polycystic ovary syndrome	3.12e-06	1.69e-05	CbGpPWpGaD
